Lutetium-177-prostate-specific membrane antigen-617, in conjunction with standard care treatment, has recently demonstrated an improvement in overall survival among men with advanced-stage prostate-specific membrane antigen-positive metastatic castration-resistant PCa[17]; however, this was not given to our patient due to limited resources. This evidence concerns the gene FOLH1 and posterior cortical atrophy.